Advertisement
Singapore markets open in 2 hours 48 minutes

  • Straits Times Index

    3,272.72
    +47.55 (+1.47%)
     

  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     

  • Dow

    38,503.69
    +263.71 (+0.69%)
     

  • Nasdaq

    15,696.64
    +245.33 (+1.59%)
     

  • Bitcoin USD

    66,406.51
    -309.67 (-0.46%)
     

  • CMC Crypto 200

    1,426.91
    +12.15 (+0.86%)
     

  • FTSE 100

    8,044.81
    +20.94 (+0.26%)
     

  • Gold

    2,335.80
    -6.30 (-0.27%)
     

  • Crude Oil

    83.33
    -0.03 (-0.04%)
     

  • 10-Yr Bond

    4.5980
    -0.0250 (-0.54%)
     

  • Nikkei

    37,552.16
    +113.55 (+0.30%)
     

  • Hang Seng

    16,828.93
    +317.24 (+1.92%)
     

  • FTSE Bursa Malaysia

    1,561.64
    +2.05 (+0.13%)
     

  • Jakarta Composite Index

    7,110.81
    -7,073.82 (-49.87%)
     

  • PSE Index

    6,506.80
    +62.72 (+0.97%)
     

Company News for Jan 10, 2020

Zacks Equity Research

  • Shares of Applied Genetic Technologies Corporation AGTC gained more than 100% after the company released a positive midstage readout for its gene therapy to treat an inherited eye disorder.

  • Shares of Tiziana Life Sciences PLC TLSA surged 16.9% after disclosing a Phase 1 data which revealed that oral treatment with foralumab was well tolerated.

  • Shares of Bed Bath & Beyond Inc. BBBY lost 19.2% after the company reported adjusted loss of 38 cents per share in fiscal Q3 2019, missing the Zacks Consensus Estimate of earnings of 3 cents.

  • Shares of Innate Pharma S.A. IPHA declined 10% after the FDA put TELLOMAK trial on partial clinical hold.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Applied Genetic Technologies Corporation (AGTC) : Free Stock Analysis Report
 
Bed Bath & Beyond Inc. (BBBY) : Free Stock Analysis Report
 
Tiziana Life Sciences PLC Sponsored ADR (TLSA) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research